![1blocker vs refine 2017 1blocker vs refine 2017](https://di-uploads-pod3.dealerinspire.com/silkohonda/uploads/2016/03/2015-Honda-Crosstour-ul.jpg)
© 2015 Society for the Study of Addiction. However, confirmatory studies are required. This study provides preliminary evidence for personalized medicine using α1 -blockade to treat AD. Doxazosin may be effective selectively in AD patients with high FHDA. Post hoc analyses revealed that doxazosin significantly reduced alcohol drinking in AD patients with high FHDA and by contrast increased drinking in those with low FHDA. With FHDA as a moderator, there were significant FHDA × medication interactions for both DPW (pcorrected = 0.001, d = 1.18) and HDD (pcorrected = 0.00009, d = 1.30). There were no significant differences between groups on DPW and HDD per week. Forty-one AD individuals were randomized, 30 (doxazosin = 15) completed the treatment phase and 28 (doxazosin = 14) also completed the follow-up. Family history density of alcoholism (FHDA), severity of AD and gender were a priori moderators. Drinks per week (DPW) and heavy drinking days (HDD) per week were the primary outcomes. Doxazosin or matched placebo was titrated to 16 mg/day (or maximum tolerable dose).
#1blocker vs refine 2017 trial
A double-blind placebo-controlled randomized clinical trial was conducted in AD individuals seeking outpatient treatment. The α1 -blocker doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been studied for AD. Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients.